Glucose abnormalities detected by continuous glucose monitoring are common in young children with Cystic Fibrosis

Prentice, Bernadette; Ooi, Chee Y.; Verge, Charles F.; Hameed, Shihab A.; Widger, John

doi:10.1016/j.jcf.2020.02.009

Cited by 25 publications

(19 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The number of enrolled patients ranged from 11 to 152 and age ranged from a few months-old to less than 10 years of age ( Table 7 ). The analysis of these studies showed that in infants and young children with CF glucose derangements detected by OGTT are often diagnosed ( 3 , 27 – 31 ) (evidence Moderate) and annual diabetes screening program in patients <10 years of age increased the early detection of CFRD ( 27 , 28 , 32 ) (evidence Low), leading to a more prompt and appropriate therapeutic approach ( 32 ) (evidence Very Low). Continuous glucose monitoring may be an alternative method for detecting glucose derangements in very young children with CF ( 29 , 30 ) (evidence Moderate), particularly those with Pseudomonas Aeruginosa colonization ( 29 ) (evidence Moderate).…”

Section: Resultsmentioning

confidence: 99%

Section: Impact On Pulmonary Exacerbations and Microbiological/pathogens Colonizationmentioning

confidence: 99%

See 1 more Smart Citation

Diabetes and Prediabetes in Children With Cystic Fibrosis: A Systematic Review of the Literature and Recommendations of the Italian Society for Pediatric Endocrinology and Diabetes (ISPED)

Mozzillo¹,

Franceschi

Piona

et al. 2021

Front. Endocrinol.

View full text Add to dashboard Cite

Cystic fibrosis related diabetes (CFRD) is a comorbidity of cystic fibrosis (CF) that negatively impacts on its clinical course. Prediabetes is an important predictor of either CFRD development and unfavorable prognosis of CF in both pediatric and adult patients. International guidelines recommend insulin only in case of CFRD diagnosis. Whether early detection and treatment of prediabetes may contribute to improve the clinical course of CF is still debated. A subgroup of pediatric diabetologists of the Italian Society for Pediatric Endocrinology and Diabetology (ISPED) performed a systematic review of the literature based on predefined outcomes: impact of pre-diabetes on clinical outcomes and on the risk of developing CFRD; diagnosis of diabetes and pre-diabetes under 10 years of age; effectiveness of therapy on glycemic control, impact of therapy on pulmonary function and nutritional status. Thirty-one papers were selected for the analysis data presented in these papers were reported in tables sorted by outcomes, including comprehensive evidence grading according to the GRADE approach. Following the grading of the quality of the evidence, the entire ISPED diabetes study group achieved consensus for the Italian recommendations based on both evidence and clinical experience. We concluded that in patients with CF, prediabetes should be carefully considered as it can evolve into CFRD. In patients with CF and prediabetic conditions, after complete evaluation of the OGTT trend, glucometrics, glycemic values measured during pulmonary exacerbations and/or steroid therapy, early initiation of insulin therapy could have beneficial effects on clinical outcomes of patients with CF and prediabetes.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Impact On Pulmonary Exacerbations and Microbiological/pathogens Colonizationmentioning

confidence: 99%

Diabetes and Prediabetes in Children With Cystic Fibrosis: A Systematic Review of the Literature and Recommendations of the Italian Society for Pediatric Endocrinology and Diabetes (ISPED)

Mozzillo¹,

Franceschi

Piona

et al. 2021

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…In a pilot study of 11 children with CF <10 years of age (median age at study entry of 3.8 (±2.5) years), Prentice et al 22 used continuous glucose monitoring (CGM) over 3 days, with repeated CGM after 12 and 24 months. Normal glucose at all time points was only seen in 27% (n=3).…”

Section: Cystic Fibrosis Related Diabetesmentioning

confidence: 99%

Year in Review 2020: Multisystemic Impact of Cystic Fibrosis

Sharma

Sathe

Savant

2021

Preprint

View full text Add to dashboard Cite

Clinical care in cystic fibrosis (CF) has continued to advance over the last several years, particularly with the widespread eligibility and use of highly effective modulator therapy. Awareness of the multisystem concerns that face persons with CF (PwCF) has also continued to be recognized as an important aspect of the burden of the disease. This review will cover a broad array of topics, from diagnosis to multisystem effects related to mental health, endocrine, palliative care, reproductive health, otolaryngology, and cardiac issues. Additionally, an understanding of worldwide care delivery will be reviewed, demonstrating variation in outcomes based on resources and populations served, ranging from the advances in care in the United States (US) to the challenges of disease recognition and diagnosis in low-and-middle-income countries (LMIC). This review is the third in a three-part CF Year in Review 2020 series, focusing on the multi-system effects of CF. Part one focused on the literature related to CFTR (cystic fibrosis transmembrane conductance regulator protein) modulators, while part two focused on pulmonary outcomes, radiographic and physiologic assessments, as well as infection and inflammation. Part three has been split into two individual parts, Part 3A presented here, and Part 3B related to CF specific nutrition and gastrointestinal publications will also be published this year. This review focuses on articles from Pediatric Pulmonology but also includes articles published in 2020 from other journals that are of particular interest to clinicians.

show abstract

“…Thus, the authors sought to describe the glucose findings from CGM in young children in a longitudinal fashion. In a pilot study of 11 children with CF < 10 years of age (median age at study entry of 3.8 ± 2.5 years), Prentice et al 22 used CGM over 3 days, with repeated CGM after 12 and 24 months. Normal glucose at all time points was only seen in 27% ( n = 3).…”

Section: Diagnosismentioning

confidence: 99%

Year in Review 2020: Multisystemic impact of cystic fibrosis

Sharma

Sathe

Savant

2021

Pediatric Pulmonology

View full text Add to dashboard Cite

Clinical care in cystic fibrosis (CF) has continued to advance over the last several years, particularly with the widespread eligibility and use of highly effective modulator therapy. Improved outcomes and longevity of persons with CF (PwCF) have increased recognition of the multisystem impact of the disease on the daily lives of PwCF. This review will cover a broad array of topics, from diagnosis to multisystem effects related to mental health, endocrine, palliative care, reproductive health, otolaryngology, and cardiac issues. Additionally, worldwide care delivery will be reviewed, demonstrating variation in outcomes based on resources and populations served. This review is part of the CF Year in Review 2020 series, focusing on the multi‐system effects of CF. This review focuses on articles from Pediatric Pulmonology but also includes articles published in 2020 from other journals that are of particular interest to clinicians.

show abstract

Glucose abnormalities detected by continuous glucose monitoring are common in young children with Cystic Fibrosis

Cited by 25 publications

References 9 publications

Diabetes and Prediabetes in Children With Cystic Fibrosis: A Systematic Review of the Literature and Recommendations of the Italian Society for Pediatric Endocrinology and Diabetes (ISPED)

Diabetes and Prediabetes in Children With Cystic Fibrosis: A Systematic Review of the Literature and Recommendations of the Italian Society for Pediatric Endocrinology and Diabetes (ISPED)

Year in Review 2020: Multisystemic Impact of Cystic Fibrosis

Year in Review 2020: Multisystemic impact of cystic fibrosis

Contact Info

Product

Resources

About